Pure Global

A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer - Trial NCT06029127

Access comprehensive clinical trial information for NCT06029127 through Pure Global AI's free database. This Phase 2 trial is sponsored by BeiGene and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06029127
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06029127
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
A Phase 2, Open-label, Randomized, Multi-arm Study of BGB-A445 in Combination With Investigational Agents in Non-Small Cell Lung Cancer Patients Previously Treated With Anti-PD-(L)1 Antibody

Study Focus

BGB-A445

Interventional

drug

Sponsor & Location

BeiGene

Timeline & Enrollment

Phase 2

Oct 01, 2023

May 01, 2026

100 participants

Primary Outcome

Overall Response Rate

Summary

The main objective of this study is to evaluate the anti-tumor activity of BGB-A445 plus
 investigational agents in participants with non-small cell lung cancer (NSCLC)

ICD-10 Classifications

Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

ClinicalTrials.gov

NCT06029127

Non-Device Trial